Follitropin delta – experience from clinical practice

1. Lunenfeld B, Bilger W, Longobardi S et al. The development of gonadotropins for clinical use in the treatment of infertility. Front Endocrinol (Lausanne) 2019; 10: 429. doi: 0.33 89/ fendo.2019.00429.

2. Bagócsi T, Rumpík D, Křenek O et al. Nový nástroj pro personalizaci ovariální stimulace: výsledky studie CERES při použití nového gonadotropinu – folitropinu delta. Ceska Gynekol 2021; 86 (2): 86–92. doi: 10.48095/cccg202 186.

3. Bousfield GR, Dias JA. Synthetis and secretion of gonadotropins including structure-function correlates. Rev Endocr Metab Disord 2011; 12 (4): 289–302. doi: 10.1007/s11154-011-91 91-3.

4. Shao F, Jiang Y, Ding S et al. Pharmacokinetics and safety of follitropin delta in gonadotropin down-regulated healthy chinese women. Clin Drug Investig 2023; 43 (1): 37–44. doi: 10.1007/s40261-022-01232-9.

5. Steward RG, Lan L, Shah AA et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril 2014; 101 (4): 967–73. doi: 10.1016/j.fertnstert.2013.12.026.

6. Fleming R, Seifer DB, Frattarelli JL et al. Assessing ovaria: antral follicle count versus anti-Müllerain hormone. Reprod Biomed Online 2015; 31 (4): 486–96. doi: 10.1016/j.rbmo.2015.06.015.

7. Moolhuijsen LM, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian functions. J Clin Endocrinol Metab 2020; 105 (11): 3361–3373. doi: 10.1210/ clinem/dgaa513.

8. Aboulghar M. Symposium: update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online 2009; 19 (1): 33–42. doi: 10.1016/s1472-6483 (10) 60043-0.

9. Corbett S, Shmorgun D, Claman P. The prevention of ovaria hyperstimulation syndrome. J Obstet Gynaecol Can 2014; 36 (11): 1024–1033. doi: 10.1016/S1701-2163 (15) 30417-5.

10. Blockeel C, Griesinger G, Rago R et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Front Endocrinol (Lausanne) 2022; 13: 992677. doi: 10.3389/fendo.2022.992677.

11. Nyboe Andersen A, Nelson SM, Fauser BC et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril 2017; 107 (2): 387.e4–396.e4. doi: 10.1016/ j.fertnstert.2016.10.033.

12. Bosch E, Havelock J, Martin FS et al. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online 2019; 38 (2): 195–205. doi: 10.1016/j.rbmo.2018.10.012.

13. Qiao J, Zhang Y, Liang X et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod 2021; 36 (9): 2452–2462. doi: 10.1093/humrep/deab155.

14. Ishihara O, Arce JC. Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ ICSI patients: a randomized controlled trial. Reprod Biomed Online 2021; 42 (5) : 909–918. doi: 10.1016/ j.rbmo.2021.01.023.